Home / Tess Bryan (page 4)

Tess Bryan

Tess Bryan is an influential Health & Travel blogger helping businesses worldwide to connect with their ideal audience and sharing great citizen journalism. Connect with her via Linkedin to share your story.

Effient (prasugrel)

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) July 2016 USE IN SPECIFIC POPULATIONS PLLR Conversion: Pregnancy Risk Summary There are no data with Effient use…

Read More »

Dulera (formoterol fumarate, mometasone furoate)

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) July 2016 USE IN SPECIFIC POPULATIONS PLLR Conversion: Pregnancy Risk Summary There are no randomized clinical studies… Powered by WPeMatico

Read More »

Dexilant (dexlansoprazole delayed-release capsules)

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) July 2016 ADVERSE REACTIONS Clinical Trials Experience Pediatrics (additional section added) The safety of DEXILANT…

Read More »

Clinolipid (lipid injectable emulsion)

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) July 2016 ADVERSE REACTIONS Post-marketing Experience Immune System Disorders: Hypersensitivity with the manifestations of rash..

Read More »

Alinia (nitazoxanide)

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) July 2016 PLR Conversion; please refer to label. ADVERSE REACTIONS (updated) Clinical Trials Experience Because clinical…

Read More »

Asmanex HFA (mometasone furoate)

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) July 2016 USE IN SPECIFIC POPULATIONS PLLR Conversion: Pregnancy Risk Summary There are no randomized clinical studies…

Read More »

Dysport (abobotulinumtoxinA)

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) July 2016 ADVERSE REACTIONS The following serious adverse reactions are discussed below and elsewhere in labeling: (additions) …

Read More »